Many studies using neoadjuvant agents demonstrate an increase in the proportion of the BCS (CD44+/CD24−) in the residual cancer status after neoadjuvant treatment, suggesting that these cells may indeed be resistant to these therapies and escape current therapies to target the cancer stem cell component [16, 26]. Here, CD44 is linked to cancer.